- Home
- HEPS vs AUPH Comparison
HEPS vs AUPH Comparison
Compare HEPS & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEPS
- AUPH
- Stock Information
- Founded
- HEPS 2000
- AUPH 1993
- Country
- HEPS Turkey
- AUPH Canada
- Employees
- HEPS N/A
- AUPH N/A
- Industry
- HEPS Catalog/Specialty Distribution
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- HEPS Consumer Discretionary
- AUPH Health Care
- Exchange
- HEPS Nasdaq
- AUPH Nasdaq
- Market Cap
- HEPS 1.1B
- AUPH 1.0B
- IPO Year
- HEPS 2021
- AUPH 1999
- Fundamental
- Price
- HEPS $2.81
- AUPH $8.86
- Analyst Decision
- HEPS
- AUPH Strong Buy
- Analyst Count
- HEPS 0
- AUPH 3
- Target Price
- HEPS N/A
- AUPH $10.33
- AVG Volume (30 Days)
- HEPS 1.2M
- AUPH 1.5M
- Earning Date
- HEPS 12-10-2024
- AUPH 11-07-2024
- Dividend Yield
- HEPS N/A
- AUPH N/A
- EPS Growth
- HEPS N/A
- AUPH N/A
- EPS
- HEPS N/A
- AUPH N/A
- Revenue
- HEPS $1,201,171,147.00
- AUPH $220,361,000.00
- Revenue This Year
- HEPS $42.76
- AUPH $36.52
- Revenue Next Year
- HEPS $39.63
- AUPH $19.02
- P/E Ratio
- HEPS N/A
- AUPH N/A
- Revenue Growth
- HEPS 0.97
- AUPH 38.72
- 52 Week Low
- HEPS $1.25
- AUPH $4.71
- 52 Week High
- HEPS $4.05
- AUPH $9.74
- Technical
- Relative Strength Index (RSI)
- HEPS 42.65
- AUPH 72.92
- Support Level
- HEPS $2.71
- AUPH $7.87
- Resistance Level
- HEPS $2.99
- AUPH $8.70
- Average True Range (ATR)
- HEPS 0.13
- AUPH 0.39
- MACD
- HEPS -0.06
- AUPH 0.06
- Stochastic Oscillator
- HEPS 14.29
- AUPH 90.77
About HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues, and other revenues.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.